CDIA™ iGFBP­1 Rapid Test Strip - Creative Diagnostics

Products Home >>Lateral Flow Test Kits >>CDIATM iGFBP­1 Rapid Test Strip

Contact Us

Fertility Tests | Insulin‐like growth factor‐binding protein 1 (iGFBP­1) |

CDIATM iGFBP­1 Rapid Test Strip (DTSXYL5)

* For research use only, not for use in diagnostic procedures.

Intended Use

The Insulin‐like growth factor‐binding protein 1 (iGFBP‐1) rapid test (vaginal secretion) is a visually interpreted, qualitative immunochromatographic dipstick test for detection of iGFBP‐1 in vaginal secretions during pregnancy, which is a major protein marker of the amniotic fluid in a vaginal sample. The test is intended for professional use to help diagnose the rupture of fetal membranes (ROM) in pregnant women.
  • Vaginal secretion
  • Strip

Product Introduction

General Description

Insulin‐like growth factor‐binding protein 1 (IBP‐1) known as placental protein 12 (PP12) is a protein that in humans is encoded by the IGFBP1 gene. IGF‐binding proteins (IGFBPs) is believed to be important in the regulation of fetal and neonatal  growth.  We  previously reported  that  the  profiles  of  IGFBPs  in  fetal  cord  serum  (FCS) were dependent on the growth/metabolic status of the fetus. It can be detected in cervical secretions of pregnant women  with  preterm  uterine contractions, and whether their presence  predicts  an increased  risk  of  preterm  delivery.  The  abundance  of  insulin‐like growth factor binding protein‐1 at the maternal‐fetal interface in severely preeclamptic pregnancies suggests that the binding protein may participate in the pathogenesis of the shallow  placental  invasion observed in this disorder. Low circulating insulin‐like growth factor‐I and elevated insulin‐like growth factor binding protein‐1 levels may contribute to restricted  placental  and therefore fetal growth.


The iGFBP‐1  (vaginal secretion) has been designed to detect iGFBP‐1 thrisough visual interpretation of color development in the internal strip. The membrane was immobilized with anti‐iGFBP‐1 antibodies on the test region. During the test, the specimen is allowed to react with colored anti‐iGFBP‐1 antibodies colloidal gold conjugates, which were precoated on the sample pad of the test. The mixture then moves on the membrane by a capillary action, and interact with reagents  on  the  membrane.  If  there  were enough iGFBP‐1 in specimens, a colored band will form at the T region of the membrane. Presence of colored band indicates a positive result, while its absence indicates a negative result. Appearance of a colored band at the control region serves as a procedural control. This indicates that proper volume of specimen has been added and membrane wicking has occurred.

Reagents And Materials Provided

##Individually packed test strip##: Each strip contains colored conjugates and reactive reagents pre-spreaded at the corresponding regions. 

##Specimens collection swab##: For specimens regions. 

##Specimens dilution tube with buffer##: 0.1 M Phosphate buffered saline(PBS) and preservative 

##Package insert##: For operation instruction.

Materials Required But Not Supplied

##Timer##: For timing use.

Specimen Collection And Preparation

•  The Insulin‐like growth factor‐binding protein 1 (iGFBP‐1) rapid  test  (vaginal secretion) is intended only for use with women vaginal secretion specimens.
•  The specimen is cervicovaginal secretion that is extracted into the Specimen Extraction Solution provided. A vaginal secretion sample is obtained using a sterile polyester swab from the posterior fomix of the vagina during a sterile speculum examination or, if no vaginal fluid is visible, the sample may be taken from the cervix. Take not to touch anything with the swab before taking the sample. The swab should be left in the vagina or cervix for approximately 10~15 seconds to allow it to absorb the secretion samples.
•  Open the Specimen Extraction Solution tube and put it in a vertical  position.  The specimen is extracted immediately from the  swab  by  swirling  the swab vigorously in the  extraction  solution  for  approximately  10  seconds.  Specimens  should  be  tested  as soon as possible after extraction but in any case no more than 4 hours after specimen collection and extraction. If a specimen can not be tested within this time it should be frozen. After thawing, the specimens can be tested as described below.
•  Perform  the  testing  immediately  after  the  specimen  collection. Do not leave the specimens at room temperature for prolonged periods. Specimens may be stored at 2‐8°C for up to 72 hours.
•  Bring specimens to room temperature prior to testing.
•  Pack the specimens in compliance with applicable regulations for  transportation  of etiological agents, in case they need to be shipped.

Reconstitution And Storage

•  The kit should be stored at 2‐30°C until the expiry date printed on the sealed pouch.
•  The test must remain in the sealed pouch until use.
•  ##Do not freeze.##
•  Cares should be taken to protect components in this kit from contamination. Do not use if there is evidence  of  microbial contamination  or  precipitation.  Biological contamination  of  dispensing equipments, containers or reagents can lead to false results.

Assay Procedure

##Bring tests, specimens, buffer and/or controls to room temperature (15­30°C) before use.##
1)  Remove the test from its sealed pouch, and place it on a clean, level surface. Label the  test  with  patient  or  control  identification.  To  obtain  a  best result, the assay should be performed within one hour.
2)  Hold the label area and put the strip into the extracted buffer towards the arrow label. ##Leave the strip into the buffer until you see the liquid front enter the result  area.##  Remove  the  strip  from  the  solution  and  place  it  in  a horizontalposition.
3)  As the test begins to work, you will see color move across the membrane.  
4)  Wait for the colored band to appear. The result should be ## read at 10 minutes.## Do not interpret the result after 20 minutes.

Interpretation of Results

##POSITIVE RESULT:##* A  colored  band  appears  in  the  control  band  region (C) and another colored band appears in the T band region.

##NEGATIVE RESULT:## One colored band appears in the control band region (C). No band appears in the test band region (T).
##INVALID RESULT:## Control band fails to appear. Results from any test which has not produced a control band at the specified reading time must be discarded.  Please  review  the  procedure  and  repeat  with  a  new test.  If  the  problem  persists,  discontinue  using  the  kit immediately and contact your local distributor.
##NOTE: ##
1.  The intensity of the color in test region (T) may vary depending on the concentration of aimed  substances  present  in  the  specimen.  Therefore,  any  shade of  color  in  the test region  should  be  considered  positive.  Besides,  the  substances  level  can  not be determined by this qualitative test.
2.  Insufficient  specimen  volume,  incorrect  operation  procedure,  or  performing  expired tests are the most likely reasons for control band failure.

Quality Control

•  Internal procedural controls are included in the test. A colored band appearing in the control  region  (C)  is  considered  an  internal  positive  procedural  control.  It  confirms sufficient specimen volume and correct procedural technique.  
•  External controls are not supplied with this kit. It is recommended  that  positive  and negative controls be tested as a good laboratory practice to confirm the test procedure and to verify proper test performance.


•  For professional in vitro diagnostic use only.
•  Do not use after expiration date indicated on the package. Do not use the test if its foil pouch is damaged. Do not reuse tests.
•  This kit contains products of animal origin. Certified knowledge of the origin and/or sanitary  state  of  the  animals  does  not  totally  guarantee  the  absence  of transmissible pathogenic agents. It is therefore, recommended that these products  be  treated as potentially  infectious,  and  handled  observing  the  usual  safety precautions  (do  not ingest or inhale).
•  Avoid cross‐contamination of specimens by using a new specimen collection container for each specimen obtained.
•  Read the entire procedure carefully prior to performing any tests.
•  Do not eat, drink or smoke in the area where the specimens and kits are handled. Handle all specimens as if they contain infectious agents. Observe  established precautions against microbiological hazards throughout  the  procedure  and  follow  the standard  procedures  for  proper  disposal  of  specimens.  Wear  protective  clothing  such slaboratory coats, disposable gloves and eye protection when specimens are assayed.
•  Buffered Saline contains sodium azide which may react with lead or copper plumbing to form potentially explosive metal azides. When disposing of buffered  saline  or extracted samples, always flush with copious quantities of water to prevent azide build up.
•  Do not interchange or mix reagents from different lots.
•  Humidity and temperature can adversely affect results.
•  The used testing materials should be discarded in accordance with local, state and/or federal regulations.
1.  The Insulin‐like growth factor‐binding protein 1 (iGFBP‐1) rapid  test  (vaginal secretion)  is  for  professional in  vitro diagnostic use, and should be used for the  qualitative detection of iGFBP‐1 only.
2.  As  with  all  diagnostic  tests,  a  definitive  clinical  diagnosis  should not be based on the results of a single test, but should only be made by the physician after all clinical and  laboratory findings have been evaluated.
3.  If  the  test  result  is  negative  and  clinical  symptoms  persist,  additional  testing  using other clinical methods is recommended. A negative result does not at any time preclude the possibility.
1.  Wadell,  G.  Laboratory  Diagnosis  of  Infectious  Diseases:  Principles  and  Practices.  New York: Springer‐Verlag, Volume II, 1988: 284‐300
2.  WILHELMI  I,  ROMAN  E,  SANCHEZ‐FAUQUIER  A.  Viruses  causing  gastroenteritis.  Clin Microbiol Infect. April. 2003, vol.9:247‐262
3.  Cubitt, WD (1982) Rotavirus Infection: An Unexpected Hazard in Units Caring  for the Elderly. Geriatric Medicine Today 1: 33‐38
4.  Erdemoglu and Mungan T. Significance of detecting insulin‐like growth factor binding
protein‐1  in  cervicovaginal  secretions:  Comparison  with  nitrazine  test  and  amoniotic fluid volume assessment. Acta Obstet Gynecol Scand (2004) 83: 622‐626

Related Products

  • Target: Fetal Fibronectin (fFN)
  • Method: Colloidal Gold
  • Sample:  Cervicovaginal Swab
  • Size: 20T
  • Target: Follicle-stimulating Hormone
  • Method: Colloidal gold
  • Sample:  Urine
  • Target: Human Chronic Gonadotropin
  • Method: Colloidal gold
  • Sample:  Urine
Get in touch